Efficacy and safety of intravenous daratumumab|based treatments ...

Efficacy and safety of intravenous daratumumab-based treatments ...

This study supports the efficacy and safety of DARA IV for the treatment of patients with AL amyloidosis.

Efficacy and safety of the randomized, open-label, non-inferiority ...

ORR was 41% for DARA SC and 37% for DARA IV. DARA SC retained at least 89% of the benefit of DARA IV (97.5% confidence). The ratio of GM of Ctrough for DARA ...

Efficacy and Safety of Daratumumab with Dexamethasone in ...

RI can affect up to 50% of pts with MM at presentation, highlighting the need for effective treatment options for this patient population. Daratumumab, an IgG1 ...

Efficacy and safety of daratumumab in the treatment of multiple ...

The available evidence demonstrated that the clinical application of combination regimens containing daratumumab improved the efficacy in patients with MM and ...

(PDF) Efficacy and safety of intravenous daratumumab-based ...

... A meta-analysis, including 30 studies and 997 patients, evaluated the efficacy and safety of daratumumab-based treatment for AL amyloidosis. The overall ...

Efficacy and safety of daratumumab plus bortezomib and ...

Identifier: NCT04474938). The treatment scheme was intravenous daratumumab at 16 mg/kg weekly in cycles 1-2, every 2 weeks for cycles 3-6 and ...

Daratumumab-Based Treatment for Immunoglobulin Light-Chain ...

The median duration of therapy was 9.6 months in the daratumumab group and 5.3 months in the control group. Efficacy. With a median follow-up of ...

Efficacy and Safety of Oral Ixazomib, Intravenous (IV) Daratumumab ...

The development of novel therapies has improved the prognosis for patients with MM, however most will ultimately relapse1. • The oral proteasome inhibitor ...

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV ...

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with ...

Safety and Efficacy of Subcutaneous Daratumumab | TCRM

IRRs in IV daratumumab interrupted dosing for 79 of 258 patients (31%) and led to treatment discontinuation in two patients. There were no ...

Improved efficiency of daratumumab treatment of multiple myeloma ...

In conclusion, as compared with IV administration, SC daratumumab was associated with 78%, 59%, 80% savings in terms of patient time, HCP active ...

a phase 1, dose-escalation study (MMY1003) - SpringerLink

Daratumumab monotherapy demonstrated favorable safety and efficacy in relapsed/refractory multiple myeloma (RRMM) patients in the global phase 1/2 GEN501 and ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for ...

The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with ...

Clinical efficacy of daratumumab monotherapy in patients with ...

Daratumumab also demonstrated a manageable safety profile marked by a low incidence of grade ≥3 infusion-related reactions (IRRs) and few treatment ...

Subcutaneous daratumumab in patients with relapsed or refractory ...

Intravenous daratumumab is approved for the treatment of multiple myeloma. In Part 1 of the PAVO study, a mix-and-deliver subcutaneous formulation of ...

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

In 2020, subcutaneous (SC) daratumumab was approved for the treatment of multiple myeloma, and randomized data suggest a lower rate of IRRs compared with IV ...

Articles Subcutaneous versus intravenous daratumumab in patients ...

Daratumumab (a human IgGκ CD38-targeting monoclonal antibody) has been shown to be safe and efficacious in patients with multiple myeloma as monotherapy1, 2, 3 ...

Phase 3 COLUMBA Study Investigating a Subcutaneous ...

The results showed non-inferior efficacy and pharmacokinetics for the SC administered formulation of DARZALEX compared to intravenous (IV) ...

Real-World Utilization and Safety of Daratumumab IV Rapid ...

These results suggest that treatment regimens including daratumumab rapid infusions at the third infusion or later were well-tolerated, and ...

Subcutaneous Daratumumab Comparable to Intravenous Treatment ...

The study also showed an improved safety profile with SC versus IV daratumumab ... efficacy and safety. We will expedite the clinical development ...